Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
THP-004
- Development stage
- Preclinical
- Lead developer
- THPharm
- Administration
- Oral
01
Overview
**THP-004**, also referred to as **LiraMAX**, is a THPharm investigational, daily-dose, dual-mechanism modified drug being developed for **obesity**. THPharm describes it as a combination approach incorporating a glucagon-like peptide 1 receptor agonist and an antiepileptic drug to regulate appetite-related signaling and dopamine reward pathways. The program was selected for South Korea's TIPS project in July 2023 and remains in formulation research; public pipeline aggregators classify it as preclinical. The specific active ingredients, their doses, and the exact antiepileptic component have not been publicly disclosed. ([thpharm.kr](https://thpharm.kr/))
- Other names
- LiraMAX
02
Targets
Beyond the preview
Go deeper on THP-004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on THP-004.